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Abstract
Objective: Epidemiological studies suggest that adult-onset growth hormone deficiency (AGHD)
might increase the risk of death from cardiovascular causes.
Methods: This was a 6-month double-blind, placebo-controlled, randomised, cross-over trial
followed by a 6-month open-label phase. Seventeen patients with AGHD received either
recombinant human growth hormone (rGH) (0.4mg injection daily) or placebo for 12 weeks,
underwent washout for 2 weeks, and were then crossed over to the alternative treatment for a
further 12 weeks. Cardiac magnetic resonance imaging, echocardiography, and cardiopulmonary
exercise testing were performed at baseline, 12 weeks, 26 weeks, and the end of the open phase
(12 months). The results were compared with those of 16 age- and sex-matched control subjects.
Results: At baseline, patients with AGHD had a significantly higher systolic blood pressure,
ejection fraction, and left ventricular mass than the control group, even when corrected for body
surface area. Treatment with rGH normalised the insulin-like growth factor 1 concentration
without an effect on exercise capacity, cardiac structure, or cardiac function.
Conclusion: Administration of rGH therapy for 6 to 9 months failed to normalise the functional
and structural cardiac differences observed in patients with AGHD when compared with a control
group.
Journal of International Medical Research
0(0) 1–12
! The Author(s) 2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0300060517723798
journals.sagepub.com/home/imr
1Department of Diabetes, Bradford Teaching Hospitals
NHS Foundation Trust, Bradford, West Yorkshire, UK
2Department of Academic Cardiology, Hull Royal
Infirmary, Kingston upon Hull, UK
3Academic Endocrinology, Diabetes and Metabolism, Hull
York Medical School, University of Hull, UK
4Weill Cornell Medical College Qatar, Doha, Qatar
Corresponding author:
SL Atkin, Weill Cornell Medicine Qatar, Education City,
PO Box 24144, Doha, Qatar.
Email: sla2002@qatar-med.cornell.edu
Data can be requested from Dr. Sathyapalan, who serves as
the custodian of the data.
ISRCTN number –ISRCTN94165486
Creative Commons CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial
4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and
distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.
sagepub.com/en-us/nam/open-access-at-sage).
Keywords
Growth hormone, adult-onset growth hormone deficiency, hypopituitarism, cardiac magnetic
resonance imaging, exercise capacity, cardiac structure, cardiac function
Date received: 19 March 2017; accepted: 11 July 2017
Abbreviations
GH, growth hormone; GHD, growth hor-
mone deﬁciency; AGHD, adult-onset
growth hormone deﬁciency; IGF-1, insulin-
like growth factor 1; CMR, cardiac
magnetic resonance imaging; LVM, left
ventricular mass; rGH, recombinant
growth hormone
Introduction
Epidemiological evidence suggests that
patients with both hypopituitarism and
adult-onset growth hormone deﬁciency
(AGHD) have an increased risk of cardio-
vascular disease.1–3 This higher risk of car-
diovascular disease may be related to
changes in body composition and lipid
proﬁles,4,5 abnormal vasculature with a
carotid intimal thickness greater than that
in patients without AGHD, and reduced
aortic distensibility.6–8 In addition, patients
with AGHD have a lower exercise capacity
than normal sex- and age-matched individ-
uals, and their maximal oxygen uptake is
reduced by about 25%.9,10
Although several studies have been
performed to evaluate the eﬀects of GH
replacement on cardiac indices in patients
with AGHD,11–22 whether GH replace-
ment therapy has any direct favourable
eﬀects on cardiac function remains
unclear. This lack of clarity is mainly due
to limitations in trial designs (absence of
control groups and small sample sizes) and
the use of supraphysiological GH doses.23
Cardiac magnetic resonance imaging
(CMR) has been proposed as the gold
standard method with which to minimise
the inaccuracy of cardiac imaging obtained
by conventional ultrasonic echocardiog-
raphy,24–26 which could be an additional
confounding factor to consider when a
lack of response to GH therapy is encoun-
tered. The advantage of CMR versus
standard echocardiography is that CMR
allows for noninvasive, high-resolution,
direct, sensitive, reproducible, and accurate
evaluation of the anatomy, ventricular
function, myocardial morphology, and
tissue damage in a single setting, avoiding
geometrical assumptions.27–29 CMR has
been used to investigate a variety of
cardiomyopathies, especially hypertrophic
cardiomyopathy, in addition to Turner
syndrome and Marfan syndrome.24,30–32
In contrast to echocardiography, CMR is
not limited by acoustic windows and has
superior inter-study reproducibility,
making it valuable for initial assessment
and longitudinal follow-up of patients.27
Arrhythmias and an inability to hold the
breath are not contraindications for CMR
but can lead to a suboptimal study out-
comes. However, implanted deﬁbrillators,
pacemakers, and generally any metallic
implant are considered absolute contra-
indications for this technique.
Therefore, the primary endpoint of this
study was determination of the diﬀerence in
left ventricular mass (LVM) between
patients with AGHD and controls and
elucidation of the change in LVM in patients
with AGHD following 6 months of treat-
ment with low-dose of recombinant human
growth hormone (rGH). The secondary
endpoints were determination of the base-
line cardiac function and exercise capacity in
controls and patients with AGHD and
observation of the changes that occur fol-
lowing treatment.
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Subjects and methods
Seventeen patients (10 male, 7 female; mean
age, 48.4 14.6 years; range, 19–74 years)
with severe AGHD conﬁrmed by a peak GH
concentration of <9 mU/L (3 ng/ml) follow-
ing an insulin tolerance test were recruited
from a tertiary centre. All patients had
hypopituitarism secondary to pituitary
tumours treated with surgery, radiotherapy,
or both. Those who had developed add-
itional pituitary hormone deﬁciencies under-
went appropriate hormone replacement and
stabilisation for at least 6 months before
being enrolled in the study. The exclusion
criteria were previous or current use of rGH
therapy, documented ischaemic heart dis-
ease, chronic heart failure, a history of
atherosclerotic vascular events, and diabetes
mellitus. A control group of 16 sex- and age-
matched healthy volunteers were recruited
by general advertisement. All participants
provided written informed consent. The
study was performed in accordance with
the declaration of Helsinki and was
approved by the local ethics committee.
The trial registration number is
ISRCTN94165486.
The patients were randomised using a
random generator table and, using a cross-
over design, allocated to either study group
A or B. Group A completed a 12-week
course of daily subcutaneous injections of
rGH at 0.4mg/day (Humatrope; Eli Lilly
and Company, Indianapolis, IN, USA) fol-
lowed by a 2-week washout period and then
received 12 weeks of placebo injections
(sterile diluent containing glycerol and
m-cresol). Group B began treatment with
placebo injections, and following the wash-
out period, initiated rGH injections for the
same time period. After the cross-over phase
was completed, the patients entered a fur-
ther 6-month open-label arm in which they
were treated with rGH only.
The ejection fraction, stroke volume,
cardiac output, end-diastolic volume, end-
systolic volume, and LVM were determined
using a 1.5-Tesla CMR system (Philips
Healthcare, Best, the Netherlands), with
subsequent analysis performed using ana-
lytical MRI-MASS software (Medis,
Leiden, the Netherlands). The LVM was
corrected to the body surface area.
Echocardiography was also performed sim-
ultaneously with routine two-dimensional
and Doppler measurements taken accord-
ing to the American Society of
Echocardiography guidelines.
Exercise capacity was evaluated with a
modiﬁed Bruce treadmill protocol. During
the tests, patients wore a tightly ﬁtting
facemask connected to a capnograph and a
sample tube enabling online measurement of
ventilation and metabolic gas exchange
(Oxycon Delta system; Jaeger, Hoechberg,
Germany). A respiratory exchange ratio of
>1, calculated as the peak carbon dioxide
production divided by the peak oxygen
production, was considered to indicate max-
imal eﬀort.
The serum concentration of insulin-like
growth factor 1 (IGF-1) was measured
using a solid-phase enzyme-labelled chemi-
luminescent immunocentric assay on an
Immulite 2000 analytical platform
(Siemens/DPC, DPC-UK, Llanberis,
Caernarfon, UK.)
All parameters were measured at base-
line, 12 weeks, 26 weeks, and the end of the
open-label phase. A ﬂow chart of the study
design is shown in Appendix 1.
Statistical analysis
Based on a previous study,33 13 participants
were needed to detect a clinically signiﬁcant
10-g change in the LVM using CMR.
Diﬀerences in the measured variables
under each of the four conditions (baseline,
GH response, control response, and GH
response) in the open-label phase response
were compared using repeated-measures
analysis of variance. The level of signiﬁcance
was set at P< 0.05.
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Results
The baseline characteristics of the patients
are shown in Appendix 1. Seventeen patients
were enrolled in the trial, and all completed
the GH/placebo arms of the study. Two
patients were excluded from the CMR ana-
lysis: Patient 16 did not complete the CMR
part of the study because he had an intra-
cranial clip, and Patient 8 was excluded
because he developed GHD after treatment
for acromegaly, which could have made
interpretation of any ﬁndings impossible
due to his previous GH excess. The median
time from diagnosis to inclusion in the trial
was 22 months. All patients were compliant
with the subcutaneous rGH injections and
had no signiﬁcant side eﬀects.
Comparisons between patients and con-
trols are shown in Table 1. Patients with
AGHD had signiﬁcantly higher systolic
blood pressure (P¼ 0.04), ejection fraction
(P¼ 0.009), stroke volume (P¼ 0.05), LVM
(P¼ 0.003), and LVM index (P¼ 0.01) than
controls. However, the patients with AGHD
exercised for a shorter period of time and had
a lower exercise capacity with a lower peak
oxygen consumption (P< 0.001), anaerobic
threshold (P¼ 0.001), and heart rate at peak
exercise (P¼ 0.006). The peak respiratory
exchange ratio was not signiﬁcantly diﬀerent
between the two groups, suggesting that
similar levels of eﬀort were attained.
The IGF-1 concentration normalised in
all treated patients in the active phase
Table 1. Comparison of CMR and cardiopulmonary exercise test measurements between
patients with AGHD and age- and sex-matched normal subjects at baseline.
Controls AGHD P value
Heart rate (beats/min) 68 (11) 75 (14) 0.18
Systolic BP (mmHg) 131 (13) 143 (18) 0.04*
Diastolic BP (mmHg) 86 (11) 93 (15) 0.14
BSA (m2) 1.90 (0.17) 2.09 (0.18) 0.005*
EF (%) 67.4 (4.5) 72.3 (5.4) 0.009*
SV (ml) 85.0 (12.4) 98.9 (23.9) 0.05*
CO (L/h) 5758 (967) 6108 (1385) 0.41
ESV (ml) 42.1 (11.7) 35.1 (12.9) 0.11
EDV (ml) 127.2 (23.0) 132.2 (32.9) 0.62
LVM (g) 114.9 (27.4) 144.4 (28.9) 0.003*
LVMI (g/m2) 59.8 (10.2) 69.1 (10.4) 0.01*
Peak VO2 40.8 (7.1) 26.3 (6.4) <0.001*
VE/VCO2 27.5 (1.9) 27.8 (4.1) 0.79
AT 26.9 (9.5) 15.5 (4.3) 0.001*
Peak RER 1.09 (0.09) 1.11 (0.08) 0.51
Exercise time (s) 982 (312) 702 (279) 0.01*
At maximal exercise
Pulse (beats/min) 177 (14) 152 (31) 0.006*
Systolic BP (mmHg) 202 (24) 193 (23) 0.29
Diastolic BP (mmHg) 103 (29) 102 (23) 0.91
Values are expressed as mean (standard deviation). The level of significance was calculated using repeated-
measures Student’s t-test. CMR, cardiac magnetic resonance imaging; AGHD, adult-onset growth hormone
deficiency; BP, blood pressure; BSA, body surface area; EF, ejection fraction; SV, stroke volume; CO, cardiac
output; ESV, end-systolic volume; EDV, end-diastolic volume; LVM, left ventricular mass; LVMI, left ventricular
mass index; VO2, peak oxygen consumption; VE/VCO2, slope of the relation between ventilation and carbon
dioxide production; AT, anaerobic threshold; RER, respiratory exchange ratio.
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(P¼ 0.005). Treatment with rGH had no
eﬀect on any of the CMR or exercise
variables during the cross-over phase, and
further changes were not observed during
the 6-month open-label extension phase in
which the patients continued with rGH
therapy. No modiﬁcation in the left ven-
tricular dimensions was observed on echo-
cardiography. Doppler echocardiography
studies revealed a prolonged mitral E wave
deceleration time and isovolumic relaxation
time (Table 2).
Discussion
This study has shown that patients with
AGHD have a lower exercise capacity than
controls but normal left ventricular func-
tion. Exercise capacity was not corrected by
a low dose of GH replacement, suggesting
that longer treatment is required for GH
to contribute to cardiac functional
remodelling.
The association between AGHD and
cardiovascular changes is controversial.
Our baseline observations that patients
with AGHD had lower exercise capacity
without left ventricular systolic dysfunction
are in accordance with previous stu-
dies.13,34–37 Conversely, other researchers
have reported a decreased LVM14,16,17,20,38
and reduced ejection fraction on echocardi-
ography38,39 or radionuclide angiography20
in patients with GHD. However, when
CMR is used, 1 year of GH treatment did
not inﬂuence cardiac mass or contractil-
ity.34,40 Similarly, in the present study,
untreated AGHD was not associated with
reduced systolic function or reduced LVM
at baseline compared with controls. This
could explain the absence of the increase in
systolic function with GH treatment.
GH was originally thought to only regu-
late somatic growth, but it has profound
eﬀects on several physiological processes
that can be aﬀected by GHD. It is involved
in the maintenance of skeletal muscle mass
and strength, body composition, and fuel
metabolism.41 Animal studies have shown
that GH aﬀects the development and main-
tenance of the heart both directly and indir-
ectly (via IGF-1)42; thus, cardiac health
could be aﬀected by GHD. GH increases
myocardial muscle mass and converts the
contractile protein myosin to a more force-
ful phenotype (low adenosine triphosphate
V3 isoform).43 Myocytes treated with GH
express increased levels of sarcoplasmic
reticulum calcium adenosine triphosphate 2
(SERCA2) mRNA and protein.44
Several trials examining the eﬀects of GH
treatment on cardiac structure and function
in patients with GHD have been published.
In a meta-analysis of 16 trials (9 blinded, 7
open) conducted in 2003, 468 patients under-
went echocardiography for assessment of the
left ventricle.45 The authors concluded that
GH administration resulted in an increase in
the left ventricular dimensions (septum,
posterior wall, and left ventricular diastolic
dimension), mass, and stroke volume.
Since the publication of this meta-analysis,
however, conﬂicting results have been
reported.11–17,34,38,46–49 Factors such as the
severity and age of onset of GHD, timing of
the initiation of GH treatment, concomitant
use of replacement therapy or other medica-
tions, and cardiovascular risk factors could
account for these discrepancies. Because of
the high sensitivity of CMR, studies based
on these techniques should have suﬃcient
statistical power to detect clinically signiﬁ-
cant changes with fewer patients.26,33,50 In
contrast, the limitations of echocardiog-
raphy mean that a minimum of 132 patients
is required to accurately measure the same
change with echocardiography.51
Exercise capacity is consistently lower
than normal in patients with
AGHD.9,10,52,53 In some controlled trials,
the peak oxygen consumption increased
with GH replacement,9,52,10,53 although the
eﬀect disappeared in one patient when the
peak oxygen consumption was corrected for
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Table 2. Comparison of CMR and cardiopulmonary exercise test measurements between patients with
AGHD and age- and sex-matched normal subjects at baseline, after 3 months of placebo or 3 months of
growth hormone therapy, and after 6 months of open-label growth hormone therapy.
Baseline Placebo Active 12 months P value
Heart rate (beats/min) 75 (14) 83 (11) 84 (15) 83 (14) 0.28
Systolic BP (mmHg) 143 (19) 143 (18) 141 (18) 135 (15) 0.49
Diastolic BP (mmHg) 93 (15) 90 (12) 88 (13) 86 (11) 0.39
IGF-1 (mg/L) 114.6 (47.4) 122.8 (53.4) 185.2 (72.8) 154.2 (45.2) <0.001
CMR
EF (%) 72.3 (5.4) 70 (5.6) 69.2 (6.1) 70.5 (7.1) 0.59
SV (ml) 98.9 (23.9) 93.1 (22.7) 90.6 (20.7) 95.4 (19.5) 0.85
CO (L/h) 6108 (1385) 6071 (1152) 6117 (1422) 6010 (1082) 0.99
ESV (ml) 35.1 (12.9) 39.9 (14.6) 41.0 (11.3) 41.3 (16.7) 0.6
EDV (ml) 132.2 (32.9) 129.6 (37.4) 130.2 (31.4) 132.9 (33.5) 0.99
LVM (g) 144.4 (22.9) 144.0 (28.9) 138.2 (22.6) 138.6 (30.6) 0.87
LVM/BSA (g/m2) 69.1 (10.4) 68.5 (12.5) 65.4 (8.3) 66.2 (12.7) 0.77
Cardiopulmonary exercise test
Peak VO2 26.3 (6.4) 24.1 (7.9) 23.5 (7.4) 22.7 (5.1) 0.48
VE/VCO2 27.8 (4.0) 27.2 (4.5) 28.5 (5.8) 27.3 (6.9) 0.9
AT 15.5 (4.2) 15.3 (4.9) 15.4 (5.9) 15.9 (5.1) 0.99
Peak RER 1.11 (0.08) 1.08 (0.14) 1.06 (0.15) 1.19 (0.20) 0.11
Exercise time (s) 702 (279) 734 (254) 653 (244) 732 (238) 0.78
Heart rate at max exercise (beats/min) 152 (31) 151 (30) 147 (26) 151 (22) 0.95
Systolic BP (mmHg) at max exercise 193 (23) 195 (29) 183 (29) 182 (28) 0.42
Diastolic BP (mmHg) at max exercise 102 (23) 106 (25) 102 (19) 87 (16) 0.06
Echocardiogram
Ao (cm) 3.0 (0.4) 2.8 (0.3) 2.9 (0.4) 3.0 (0.3) 0.64
LA (cm) 3.4 (0.7) 3.3 (0.6) 3.7 (0.8) 3.8 (0.6) 0.14
LVDd (cm) 5.1 (0.5) 4.8 (0.8) 5.1 (0.6) 4.9 (0.7) 0.33
LVDs (cm) 3.4 (0.9) 3.3 (1.0) 3.4 (1.1) 3.3 (1.0) 0.99
IVS (cm) 1.0 (0.2) 1.1 (0.2) 1.1 (0.3) 1.1 (0.3) 0.96
PW (cm) 1.3 (0.3) 1.1 (0.4) 1.1 (0.3) 0.9 (0.2) 0.21
EF (%) 65 (9) 58 (7) 63 (10) 61 (7) 0.05*
MVe (m/s) 0.8 (0.1) 0.7 (0.2) 0.7 (0.1) 0.7 (0.2) 0.04*
MVa (m/s) 0.7 (0.2) 0.6 (0.2) 0.6 (0.2) 0.6 (0.2) 0.6
E/A 1.2 (0.3) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 0.94
DT (ms) 211 (40) 270 (58) 222 (56) 255 (64) 0.02*
IVRT (ms) 89 (11) 91 (21) 86 (25) 119 (20) <0.001*
Values are expressed as mean (standard deviation). The level of significance was calculated using a repeated-measures
analysis of variance F-test (sphericity assumed). CMR, cardiac magnetic resonance imaging; AGHD, adult-onset growth
hormone deficiency; BP, blood pressure; IGF-1, insulin-like growth factor 1; SV, stroke volume; CO, cardiac output; ESV,
end-systolic volume; EDV, end-diastolic volume; LVM, left ventricular mass; VO2, peak oxygen consumption; VE/VCO2,
slope of the relation between ventilation and carbon dioxide production; AT, anaerobic threshold; RER, respiratory
exchange ratio; Ao, aorta; LA, left atrium; LVDd, left ventricular dimension in diastole; LVDs, left ventricular dimension in
systole; IVS, interventricular septal dimension in diastole; PW, posterior wall of left ventricular dimension in diastole; EF,
ejection fraction of left ventricle; MVe, mitral valve E wave; MVa, mitral valve Awave; E/A, ratio of mitral E wave over Awave;
DT, mitral E wave deceleration time; IVRT, isovolumic relaxation time.
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body mass.10 Other similarly designed stu-
dies have not shown any such eﬀect on
exercise performance.51,54–56
We found changes in exercise capacity
and cardiac structure and function similar to
those in previous studies. However, we
found no change in cardiac structure or
function using the gold standard method of
assessment (CMR) and no change in exer-
cise capacity as assessed by cardiopulmon-
ary exercise testing after GH replacement.
This occurred despite achieving physio-
logical GH replacement as shown by nor-
malisation of IGF-1. However, we did
observe some minor changes in diastolic
function with prolongation of the mitral E
wave deceleration time and isovolumic
relaxation time, suggesting mild left ven-
tricular diastolic impairment.
In this study, systolic function was
normal in patients with AGHD, and their
LVM was greater than in normal subjects.
This observation persisted when the left
ventricular mass was corrected for the
body surface area. The explanation for
this diﬀerence may be the higher blood
pressure in the patients with AGHD than
in the normal subjects. Further diﬀerences
between our study and others were caused
by the lack of eﬀect of GH therapy despite
a signiﬁcant increase in the IGF-1 concen-
tration. Our observations on exercise cap-
acity are in agreement with those of other
groups who showed little change with GH
therapy.54
It is possible that our patients diﬀered
from those of previous study populations.
The patients were heterogeneous with
respect to the duration of untreated
AGHD and underlying diseases. The dur-
ation of AGHD may have been insuﬃcient
for the development of systolic dysfunction.
Considering that the half-life of rGH is
around 4 hours, the wash-out period for
the study was set at 2 weeks. However, it is
possible that the eﬀects of GH could have
lasted longer and thus aﬀected the results.
Ideally, GH therapy should be titrated based
on the IGF-1 response to optimise the
outcome; however, we had to use a ﬁxed
dose of GH because titration of GH would
have resulted in unblinding of the study. All
but one of our patients presented with GHD
as adults, and previous groups have
reported diﬀerences between patients who
develop GHD in childhood and those who
develop it in adulthood. Those with GHD as
children have a lower left ventricular wall
thickness and mass.57,58 Several eﬀects of
GH might inﬂuence long-term cardiovascu-
lar outcomes,59,60 but these were not
explored in the present study. Our study
supports the need for long-term GH treat-
ment to manage the functional cardiac
abnormalities that may occur in patients
with severe GHD.
Conclusion
This study conﬁrms that patients with
AGHD have a lower exercise capacity,
greater LVM, and normal systolic function
compared with controls. While GH therapy
normalised the IGF-1 concentration in
patients with AGHD, there was no change
in the exercise capacity, cardiac structure, or
cardiac systolic function during the 9
months of GH treatment.
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Appendix 1. Flow chart of patient progression through the trial and
those who underwent CMR: 15 patients with AGHD compared with 16
age- and sex-matched controls
17 patients with growth hormone deficiency and all completed growth 
hormone cross over trial. However, 16 patients with GH deficiency 
underwent the CMR (1 excluded due to metallic implant) 16 completed but 
1 excluded from analysis of CMR because of treated acromegaly.  
                       16 patients with GH deficiency randomised 
GH – 0.4mg s/c daily 
 x 12 weeks 
n=8 
Withdrawal=0 
CMR, Echo, cardiopulmonary 
exercise testing at 12 weeks 
h
Placebo – 0.4mg s/c daily 
 x 12 weeks 
n=8 
Withdrawal=0 
CMR, Echo, cardiopulmonary 
exercise testing at 12 weeks 
Placebo – 0.4mg s/c daily 
 x 12 weeks 
n=8 
Withdrawal=0 
CMR, Echo, cardiopulmonary 
exercise testing at the end of 12 
weeks 
GH – 0.4mg s/c daily 
 x 12 weeks 
n=8 
Withdrawal=0 
CMR, Echo, cardiopulmonary 
exercise testing at the end of 
12 weeks 
Washout & 
Cross over (2 weeks) 
GH – 0.4mg s/c daily 
 x 24 weeks 
n=8 
Withdrawal=0 
CMR, Echo, cardiopulmonary 
exercise testing at the end of 
24 weeks 
GH – 0.4mg s/c daily 
 x 24 weeks 
n=8 
Withdrawal=0 
CMR, Echo, cardiopulmonary 
exercise testing at the end of 
24 weeks 
Total completed = 16 
CMR, cardiac magnetic resonance imaging; AGHD, adult-onset growth hormone deﬁciency;
GH, growth hormone.
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